Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
71 hedge funds and large institutions have $332M invested in Avadel Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 25 reducing their positions, and 6 closing their positions.
137% more call options, than puts
Call options by funds: $1.45M | Put options by funds: $611K
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
11% more funds holding
Funds holding: 64 → 71 (+7)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less capital invested
Capital invested by funds: $342M → $332M (-$10.3M)
16% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.64M |
| 2 |
PC
PointState Capital
New York
|
+$5.75M |
| 3 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$4.42M |
| 4 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
+$2.71M |
| 5 |
Morgan Stanley
New York
|
+$2.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$9.45M |
| 2 |
BC
Broadfin Capital
New York
|
-$3.77M |
| 3 |
PA
Perceptive Advisors
New York
|
-$2.73M |
| 4 |
Millennium Management
New York
|
-$2.21M |
| 5 |
Jennison Associates
New York
|
-$1.55M |
AVDL Hedge Fund Activity: Q3 2014 in Review
71 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2014, worth a combined $332M — down 3% from $342M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new AVDL positions and 6 closed out — a net gain of 7 holders — while 21 added to existing stakes and 25 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $6.64M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $9.45M sold.
- 71 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2014, up from 64 in Q2 2014.
- Funds reported $332M of Avadel Pharmaceuticals stock for Q3 2014, down 3% quarter-over-quarter.
- 13 funds opened new Avadel Pharmaceuticals positions in Q3 2014 and 6 closed out, a net change of +7 holders.
- The largest Avadel Pharmaceuticals buyer in Q3 2014 was T. Rowe Price Associates, an estimated $6.64M added.
- The largest Avadel Pharmaceuticals seller in Q3 2014 was Consonance Capital Management, an estimated $9.45M sold.
Based on aggregated 13F filings for Q3 2014.